Clostridium Difficile
5
Pipeline Programs
6
Companies
6
Clinical Trials
1 recruiting
1
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
1
2
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Vaccine
150%
Monoclonal Antibody
150%
+ 4 programs with unclassified modality
On Market (1)
Approved therapies currently available
M&
Competitive Landscape
4 companies ranked by most advanced pipeline stage
M&
Merck & Co.RAHWAY, NJ
3 programs1
BezlotoxumabPhase 4Monoclonal Antibody1 trial
Relationship Between C. Difficile Toxins' Serum Level With C. Difficile InfectionN/A1 trial
Systematic evaluation by an ID expert.N/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
Merck & Co.Bezlotoxumab
Vedanta BiosciencesVE303
Seres TherapeuticsSER-109
PfizerC. difficile vaccine with adjuvant
Merck & Co.Relationship Between C. Difficile Toxins' Serum Level With C. Difficile Infection
Merck & Co.Systematic evaluation by an ID expert.
Clinical Trials (6)
Total enrollment: 1,485 patients across 6 trials
Bezlotoxumab as Secondary Prophylaxis for C. Difficile in High-risk Hospitalized Patients Exposed to Antibiotics.
Start: Aug 2019Est. completion: May 20221 patients
Phase 4Terminated
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
Start: May 2024Est. completion: Oct 2027852 patients
Phase 3Recruiting
SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI)
Start: May 2015Est. completion: Oct 2016
Phase 2Completed
A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 To 85 Years, Who Will Each Receive 3 Doses Of Vaccine.
Start: Jan 2014Est. completion: May 2015184 patients
Phase 1Completed
NCT03586206Merck & Co.Relationship Between C. Difficile Toxins' Serum Level With C. Difficile Infection
Relationship Between C. Difficile Toxins' Serum Level With C. Difficile Infection
Start: Sep 2018Est. completion: Dec 202045 patients
N/AUnknown
Antimicrobial Stewardship Program for Clostridium Difficile Infection.
Start: Feb 2017Est. completion: Dec 2017403 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 1,485 patients
6 companies competing in this space